Appendix 1 (part 1 of 2): Questionnaire for a study about pediatric therapeutic drug monitoring (TDM).

Note: For some questions, the survey presented the respondent with a set of options from which to choose (e.g., indicated with the phrase "Select all that apply"); the specific options are not listed here but are elaborated in the main article.

Part I

What is the name of your institution? (Note this is only to ensure data are handled per site, and all data will be deidentified and reported as aggregates)

Please indicate if you would like to participate in Part I of the survey.

In what province/territory are you working?

Is your site a university affiliated institution?

Does this site serve pediatric patients?

Does your site monitor serum drug concentrations for pediatric patients?

Is this a standalone pediatric hospital or a pediatric ward/ service within an adult centre?

How many beds are there at your site?

How many pediatric beds are there at your site?

What is your total number of patient days for the last annual period? If you do not know the answer to this question, please type "N/A" in the box provided below.

What practice model is followed by your department?

Can pharmacists independently order serum drug concentrations?

In which of the following TDM-related activities do your pharmacists participate (either independently or in consult with a prescriber)? Select all that apply.

What education do the pharmacists at your site receive regarding TDM? Select all that apply.

Does your site perform TDM for any of the following medications? (Note: this does NOT include toxicology monitoring). Also, if your site performs TDM for HIV medications or any other medications not listed here, please list them in the text boxes provided below.

- Acetaminophen
- Amikacin (extended interval dosing)
- Amikacin (traditional dosing)
- Caffeine
- Carbamazepine
- Clozapine
- Cyclosporine
- Digoxin
- Disopyramide

- Ethosuximide
- Gentamicin (extended interval dosing)
- Gentamicin (traditional dosing)
- Imipramine
- Lithium
- Lidocaine
- Methotrexate
- Phenobarbital
- Phenytoin
- Procainamide
- N-Acetylprocainamide (NAPA)
- Propranolol
- Quinidine
- Salicylate (ASA)
- Sirolimus
- Tacrolimus
- Theophylline/aminophylline
- Tobramycin (extended interval dosing)
- Tobramycin (traditional dosing)
- Valproic acid
- Vancomycin
- HIV medications
- Other

If you had selected "No" to monitoring of any of the medications listed previously, what were the reasons for no TDM? Select all that apply.

For which of the following indication(s) are serum drug concentrations routinely ordered? Select all that apply.

- Initiation of medication
- Clinical changes
- Changes in renal or hepatic function
- Adding or discontinuing an interacting medication
- Does not monitor this drug

[Question applied for 5 drug groups: aminoglycosides (extended interval dosing), aminoglycosides (traditional dosing), antiepileptics, immunosuppressants, vancomycin]

Please select what types of serum drug concentrations are routinely ordered for the following medication groups. Select all that apply.

- Peak
- Trough
- Random
- Other
- Unknown

[Question applied for 5 drug groups: aminoglycosides (extended interval dosing), aminoglycosides (traditional dosing), antiepileptics, immunosuppressants, vancomycin]

Supplementary material for Leung D, Ensom MHH, Carr R. Survey of therapeutic drug monitoring practices in pediatric health care programs across Canada. Can J Hosp Pharm. 2019;72(2):126-32.

Appendix 1 (part 2 of 2): Questionnaire for a study about pediatric therapeutic drug monitoring (TDM).

If you had selected "Other" for any medications listed in the previous question, or if you would like to clarify any of your responses above, please do so in the text boxes provided below.

- Aminoglycosides (extended interval dosing)
- Aminoglycosides (traditional dosing)
- Antiepileptics
- Immunosuppressants
- Vancomycin

What is/are the normal reference range(s) for the following drug(s) which you monitor?

- Amikacin (extended interval dosing)
- Amikacin (traditional dosing)
- Gentamicin (extended interval dosing)
- Gentamicin (traditional dosing)
- Sirolimus
- Tacrolimus
- Methotrexate
- Tobramycin (extended interval dosing)
- Tobramycin (traditional dosing)
- Vancomycin
- Cyclosporine

For the drug(s) that you have selected "Other" for in the previous question, what is/are the normal reference range(s) for these drug(s)?

- Amikacin (extended interval dosing)
- Amikacin (traditional dosing)
- Gentamicin (extended interval dosing)
- Gentamicin (traditional dosing)
- Sirolimus
- Tacrolimus
- Methotrexate
- Tobramycin (extended interval dosing)
- Tobramycin (traditional dosing)
- Vancomycin
- Cyclosporine

Is pharmacogenetic testing performed at your site?

Is pharmacogenetic testing performed at your site as part of TDM?

If you had selected "Yes" to the previous question, in what ways are pharmacists involved? Select all that apply. You may leave this <u>blank</u> if your site does not perform pharmacogenetic tests for TDM.

Please briefly describe what types of pharmacogenetic tests are performed at your site as part of TDM (<u>if applicable</u>). You may leave this <u>blank</u> if your site does not perform pharmacogenetic tests for TDM. If your site does perform pharmacogenetic tests for TDM, but you do not know what these tests are, please type "Do not know" in the box provided below.

Part II

Please indicate where TDM is done for the following medications:

- Acetaminophen
- Amikacin (extended interval dosing)
- · Amikacin (traditional dosing)
- Caffeine
- Carbamazepine
- Clozapine
- Cyclosporine
- Digoxin
- Disopyramide
- Ethosuximide
- Gentamicin (extended interval dosing)
- Gentamicin (traditional dosing)
- Imipramine
- Lithium
- Lidocaine
- Methotrexate
- Phenobarbital
- Phenytoin
- Procainamide
- N-Acetylprocainamide (NAPA)
- Propranolol
- Quinidine
- Salicylate (ASA)
- Sirolimus
- Tacrolimus
- Theophylline/aminophylline
- Tobramycin (extended interval dosing)
- Tobramycin (traditional dosing)
- Valproic acid
- Vancomycin

Please attach a copy of your data (i.e., number of drug levels) for a "representative month" for all the drugs that your lab measures (accepted file formats include PDF, Word document, Excel spreadsheet).

Supplementary material for Leung D, Ensom MHH, Carr R. Survey of therapeutic drug monitoring practices in pediatric health care programs across Canada. Can J Hosp Pharm. 2019;72(2):126-32.